Interferon alfa-2b biosimilar (Landsteiner)

干扰素α-2b生物类似药 (Landsteiner)

Report date: 2023/05/05 17:34:33

Base Information

Drug NameInterferon alfa-2b biosimilar (Landsteiner)
Drug Alias Name干扰素α-2b生物仿制药 (Landsteiner)Lanstion
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMelanomaLymphoma, FollicularLeukemia, Myelogenous, Chronic +[8] 
Global Approved IndicationsMelanomaLymphoma, FollicularLeukemia, Myelogenous, Chronic +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMexico
Original Approved Date2012/08/01
Country/TerritoryMexico
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLandsteiner Scientific
China Registration ClassN/A

Develop Information

Active CompaniesLandsteiner Scientific
Inactive CompaniesN/A
Active IndicationsMelanomaLymphoma, FollicularLeukemia, Myelogenous, Chronic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A